在ccRCC中ERLncRNAs的预后影响:一种新的风险评分模型及其与瘤突变负担和免疫微环境的关联
相关实验视频
Updated: May 26, 2025
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
6.8K
Kunlun Feng1, Jingxiang Li2, Jianye Li2
1Shandong University of Traditional Chinese Medicine, Jinan, 250013, Shandong, China.
Discover oncology
|February 22, 2025
概括
这项研究确定了长非编码RNAs (ERLncRNAs) 的七个基因签名,用于预测清细胞细胞癌 (ccRCC) 的结果和指导免疫治疗. 签名有助于评估ccRCC患者的预后和治疗反应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 在清细胞细胞癌 (ccRCC) 中,与细胞分裂相关的长非编码RNAs (ERLncRNAs) 的作用仍未得到充分研究.
- 了解这些ERLncRNA对于开发ccRCC的新诊断和治疗策略至关重要.
研究的目的:
- 在ccRCC中识别和验证ERLncRNAs的预后特征.
- 根据ERLncRNA的特征来描述免疫格局,并预测基于ERLncRNA的免疫治疗反应.
主要方法:
- 使用了癌症基因组图谱 (TCGA) 数据用于ccRCC样本.
- 采用生物信息学分析,包括皮尔森相关性,LASSO和Cox回归来开发签名.
- 评估了免疫细胞透,瘤突变负担 (TMB),瘤微环境 (TME) 和药物敏感性.
主要成果:
- 一个新的七个ERLncRNA签名 (LINC01615,RUNX3-AS1,FOXD2-AS1,AC002070.1,LINC02747,LINC00944,AC092296.1) 已经被确定.
- 该签名表现出强大的预测预测能力,由卡普兰-梅尔,ROC曲线,名谱和C指数验证.
- 免疫格局和TME特征的显著差异与签名有关.
结论:
- 开发的七个ERLncRNA签名在ccRCC中具有显著的预后预测潜力.
- 这种签名可以作为评估ccRCC患者免疫治疗反应的有价值工具.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
204
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
02:17The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K